The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biomarkers, 2025Development of an Assay for Rapid Detection of Activated LRRK2
Study Rationale: Mutations associated with Parkinson’s disease (PD) elevate the activity of a protein called Leucine-rich repeat kinase 2 (LRRK2). Kinases add phosphate groups to other proteins and to...
-
Neuronal Synuclein Disease Endotypes 2024, 2025Assessing the Aggregation of Alpha-synuclein Across Aging, Alzheimer’s Disease and Dementia with Lewy Bodies
Study Rationale: Forms of alpha-synuclein, the protein that aggregates in Parkinson’s disease (PD), can be detected in cerebrospinal fluid (CSF) by seed amplification assays (SAA). These highly...
-
Research Grant, 2025Evaluation of Novel PET Probes for Alpha-synuclein Imaging
Study Rationale: Aggregation of the protein alpha-synuclein into fibrils in Lewy bodies and Lewy neurites is the key pathological feature of Parkinson's disease (PD) and related synucleinopathies...
-
Accelerating Biological Understanding and Therapeutic Translation for PD-Biology, 2025Accelerating Biological Understanding and Therapeutic Translation for PD-Biology
Study Rationale: Mutations in the PINK1 and Parkin genes cause early-onset Parkinson’s disease (PD). In rats with similar mutations in PINK1 and Parkin, we observed pronounced degeneration of nerve...
-
Freezing of Gait Program, 2025Treating Freezing of Gait in Parkinson’s Disease Using an ADHD Drug that Reduces Neural Cross-talk: A Multi-center Multi-modal Approach
Study Rationale: Freezing of gait affects four out of five people with Parkinson’s disease (PD), yet this debilitating symptom is not fully treated by any PD medication available. Research has shown...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025Assessment of Psilocybin Therapy for Treatment of Depression in Parkinson’s Disease
Study Rationale: Depression is of the most common and disabling symptoms of Parkinson’s disease (PD), and it is linked to poor quality of life and faster disease progression. Unfortunately, we lack...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.